Novel adjuvant therapies for pancreatic adenocarcinoma

Tolutope Oyasiji, Wen Wee Ma

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.

Original languageEnglish (US)
Pages (from-to)430-435
Number of pages6
JournalJournal of Gastrointestinal Oncology
Volume6
Issue number4
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

gemcitabine
Adenocarcinoma
Pancreatic Neoplasms
Vaccines
Drug Therapy
Chemoradiotherapy
Immunotherapy
Therapeutics
Survival

Keywords

  • Adjuvant therapy
  • Immunotherapy
  • Pancreatic cancer
  • Vaccines

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Novel adjuvant therapies for pancreatic adenocarcinoma. / Oyasiji, Tolutope; Ma, Wen Wee.

In: Journal of Gastrointestinal Oncology, Vol. 6, No. 4, 01.01.2015, p. 430-435.

Research output: Contribution to journalReview article

@article{f3603deebfb843e2aa8e8ef0267dbef2,
title = "Novel adjuvant therapies for pancreatic adenocarcinoma",
abstract = "Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.",
keywords = "Adjuvant therapy, Immunotherapy, Pancreatic cancer, Vaccines",
author = "Tolutope Oyasiji and Ma, {Wen Wee}",
year = "2015",
month = "1",
day = "1",
doi = "10.3978/j.issn.2078-6891.2015.031",
language = "English (US)",
volume = "6",
pages = "430--435",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "4",

}

TY - JOUR

T1 - Novel adjuvant therapies for pancreatic adenocarcinoma

AU - Oyasiji, Tolutope

AU - Ma, Wen Wee

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.

AB - Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.

KW - Adjuvant therapy

KW - Immunotherapy

KW - Pancreatic cancer

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84995810291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995810291&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2015.031

DO - 10.3978/j.issn.2078-6891.2015.031

M3 - Review article

AN - SCOPUS:84995810291

VL - 6

SP - 430

EP - 435

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 4

ER -